Development of Pharmacoeconomic Evidence for Inflammatory Bowel Disease in China: A Systematic Review
Author(s)
Yunfeng Lai, Ph.D.1, Huimin Zou, Ph.D.1, Zhiguang Fu, Ph.D.2, Honghao Shi, Ph.D.2.
1Guangzhou University of Chinese Medicine, Guangzhou, China, 2Peking University International Research Center for Pharmaceutical Management, Beijing, China.
1Guangzhou University of Chinese Medicine, Guangzhou, China, 2Peking University International Research Center for Pharmaceutical Management, Beijing, China.
OBJECTIVES: To analyze the development of pharmacoeconomic evidence for Inflammatory Bowel Disease (IBD) in China, providing empirical references to support clinically value-oriented interventions for IBD.
METHODS: A systematic literature search was conducted across six databases (China National Knowledge Infrastructure, Wanfang, Web of Science, PubMed, Medline, and Cochrane Central) to identify clinical and real-world studies that reported the impact of IBD on cost or quality of life (QoL), published before March 28, 2025. The focus population included patients with IBD in China. This review excluded studies that did not meet the inclusion criteria.
RESULTS: A total of 18 articles were included. Among these, 4 focused on Crohn's disease, 11 on ulcerative colitis, and 3 on IBD in general. The review included 10 clinical trial studies, 6 real-world studies, and 2 literature reviews. The average sample size per study was 46.4 patients, with an average intervention duration of 85.4 days. Only 4 studies employed Markov models. Interventions included 3 studies on traditional Chinese medicine and 15 studies on monoclonal antibody interventions, primarily infliximab and vedolizumab. Cost-effectiveness analysis was predominantly conducted, with clinical response rates, clinical remission rates, and quality-adjusted life years (QALYs) being the main clinical outcome measures.
CONCLUSIONS: IBD imposes a significant economic and quality of life burden on patients, yet high-quality clinical and economic evaluation evidence remains scarce. Future research should explore the economic impact on Chinese patients and their families, the effects of physical and mental factors on quality of life, and the relationships between these factors in the region.
METHODS: A systematic literature search was conducted across six databases (China National Knowledge Infrastructure, Wanfang, Web of Science, PubMed, Medline, and Cochrane Central) to identify clinical and real-world studies that reported the impact of IBD on cost or quality of life (QoL), published before March 28, 2025. The focus population included patients with IBD in China. This review excluded studies that did not meet the inclusion criteria.
RESULTS: A total of 18 articles were included. Among these, 4 focused on Crohn's disease, 11 on ulcerative colitis, and 3 on IBD in general. The review included 10 clinical trial studies, 6 real-world studies, and 2 literature reviews. The average sample size per study was 46.4 patients, with an average intervention duration of 85.4 days. Only 4 studies employed Markov models. Interventions included 3 studies on traditional Chinese medicine and 15 studies on monoclonal antibody interventions, primarily infliximab and vedolizumab. Cost-effectiveness analysis was predominantly conducted, with clinical response rates, clinical remission rates, and quality-adjusted life years (QALYs) being the main clinical outcome measures.
CONCLUSIONS: IBD imposes a significant economic and quality of life burden on patients, yet high-quality clinical and economic evaluation evidence remains scarce. Future research should explore the economic impact on Chinese patients and their families, the effects of physical and mental factors on quality of life, and the relationships between these factors in the region.
Conference/Value in Health Info
2025-09, ISPOR Real-World Evidence Summit 2025, Tokyo, Japan
Value in Health Regional, Volume 49S (September 2025)
Code
RWD139
Topic Subcategory
Health & Insurance Records Systems
Disease
SDC: Infectious Disease (non-vaccine)